ImmuneBridge Company Profile

Background

Overview

ImmuneBridge is a biotechnology company founded in 2018 and headquartered in San Francisco, California. The company specializes in developing allogeneic cell-based immunotherapies for cancer treatment, focusing on natural killer (NK) cell therapies derived from cord blood. By leveraging its proprietary expansion technology, ImmuneBridge aims to create scalable, off-the-shelf cell therapies that are both effective and accessible.

Mission and Vision

ImmuneBridge's mission is to amplify nature's innate intelligence to fight cancer by developing high-quality, scalable cell therapies. The company's vision is to make curative cancer treatments accessible to everyone, starting with NK cell-based immunotherapies.

Industry Significance

ImmuneBridge operates in the rapidly evolving field of immuno-oncology, a sector that has seen significant advancements in recent years. The company's focus on allogeneic NK cell therapies positions it to contribute to the growing demand for effective and affordable cancer treatments. By addressing challenges related to scalability and cost, ImmuneBridge aims to make cell therapies more accessible to a broader patient population.

Key Strategic Focus

Core Objectives

• Development of Allogeneic NK Cell Therapies: ImmuneBridge is dedicated to creating off-the-shelf NK cell therapies that can be rapidly manufactured and administered to patients without the need for personalized treatments.

• Scalability and Cost Reduction: The company aims to develop scalable manufacturing processes that reduce the cost of cell therapies, making them more accessible to a wider range of patients.

Areas of Specialization

• Cord Blood-Derived Immune Stem Cells: ImmuneBridge specializes in expanding cord blood-derived immune stem cells, maintaining their multipotency to differentiate into various immune cell types, including NK cells, T cells, and macrophages.

• Natural Killer (NK) Cell Therapies: The company focuses on developing NK cell-based immunotherapies for both hematological malignancies and solid tumors.

Key Technologies Utilized

• Proprietary Expansion Technology: ImmuneBridge employs a novel small molecule to expand cord blood hematopoietic stem and progenitor cells (HSPCs) over 100,000-fold while preserving their immune multipotency.

• Machine Learning-Powered Screening: The company utilizes machine learning algorithms to optimize the selection and expansion of the most potent NK cells for therapeutic use.

Primary Markets Targeted

• Hematological Malignancies: ImmuneBridge is developing NK cell therapies for blood cancers, including leukemia and lymphoma.

• Solid Tumors: The company plans to extend its NK cell therapies to treat solid tumors, addressing a significant unmet need in cancer treatment.

Financials and Funding

Funding History

• Total Funds Raised: As of April 2026, ImmuneBridge has raised a total of $19.7 million across multiple funding rounds.

• Recent Funding Rounds:

• April 2026: The company secured an additional $7.7 million in a seed extension round led by NFX, bringing the total funding to date to $19.7 million.

• April 2023: ImmuneBridge raised $12 million in a seed financing round co-led by Insight Partners and M Ventures, with participation from One Way Ventures and Gaingels.

Notable Investors

• Insight Partners: A global venture capital and private equity firm investing in high-growth technology and healthcare companies.

• M Ventures: The strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany, focusing on investments in life sciences.

• NFX: A seed-stage venture firm that led the most recent funding round in April 2026.

Utilization of Capital

The funds raised are intended to:

• Scale Manufacturing: Enhance the production capabilities for allogeneic NK cell therapies.

• Expand Research and Development: Advance pre-clinical studies and prepare for clinical trials.

• Strengthen Partnerships: Collaborate with other biotech companies and research institutions to accelerate the development and commercialization of therapies.

Pipeline Development

Key Pipeline Candidates

• Expanded NK Cell Therapies: ImmuneBridge is developing NK cell therapies derived from expanded cord blood HSPCs, targeting both hematological malignancies and solid tumors.

Stages of Development

• Pre-Clinical Stage: The company is conducting pre-clinical studies to validate the efficacy and safety of its NK cell therapies.

• Clinical Trials: ImmuneBridge plans to initiate clinical trials for its lead NK cell therapy candidate in the near future.

Target Conditions

• Hematological Malignancies: Including leukemia and lymphoma.

• Solid Tumors: Such as breast, lung, and colorectal cancers.

Anticipated Milestones

• Pre-Clinical Data: Expected to be generated in the coming months.

• Clinical Trial Initiation: Planned for the near future, pending regulatory approvals.

Technological Platform and Innovation

Proprietary Technologies

• Expansion Technology: A novel small molecule that enables the expansion of cord blood-derived HSPCs over 100,000-fold while maintaining their multipotency.

• Machine Learning Algorithms: Utilized to optimize the selection and expansion of NK cells, enhancing the therapeutic potential of the cell therapies.

Significant Scientific Methods

• Immune Cell Differentiation: Techniques to differentiate expanded HSPCs into functional NK cells, T cells, and macrophages.

• Immuno-Oncology Assays: Assays to evaluate the anti-tumor activity of NK cells against various cancer cell lines.

AI-Driven Capabilities

• Data Analysis: Machine learning models analyze large datasets to identify optimal conditions for NK cell expansion and differentiation.

• Predictive Modeling: AI algorithms predict the efficacy of NK cell therapies in pre-clinical models, guiding research and development efforts.

Leadership Team

Executive Profiles

• Peretz Partensky: Co-founder and CEO. With a background in product and data management, Peretz has previously served as Vice President of Product and Data at Vim.

• Jesse Cotari: Co-founder and Chief Scientific Officer. An immunologist with experience in developing NK cell-based immunotherapies, Jesse has worked at Memorial Sloan Kettering Cancer Center and led the development of ImmuneBridge's HSC expansion and differentiation platform.

Key Contributions

• Peretz Partensky: Led the strategic direction and operational growth of ImmuneBridge, focusing on product development and data-driven decision-making.

• Jesse Cotari: Directed the scientific research and development efforts, establishing the foundation for ImmuneBridge's innovative NK cell therapy platform.

Competitor Profile

Market Insights and Dynamics

The immuno-oncology market, particularly the NK cell therapy segment, is experiencing rapid growth, with a total addressable market (TAM) reaching $4.4 billion in 2026 and a compound annual growth rate (CAGR) of 12%. This expansion is driven by increasing cancer prevalence and the demand for effective, scalable treatments.

Competitor Analysis

• Artiva Biotherapeutics: Focuses on off-the-shelf NK cell therapies for cancer treatment.

• Nkarta Therapeutics: Develops engineered NK cell therapies targeting various cancers.

• Fate Therapeutics: Specializes in cellular immunotherapies, including NK cell products.

• Glycostem Therapeutics: Develops NK cell-based immunotherapies for cancer.

Strategic Collaborations and Partnerships

ImmuneBridge has established collaborations with leading experts in immunology and cell therapy, including:

• Catherine Blish, MD, PhD: Professor of Medicine and Immunology at Stanford University School of Medicine.

• Aharon Freud, MD, PhD: Associate Professor in the Department of Pathology at Ohio State University.

These partnerships aim to enhance the scientific foundation and clinical development of ImmuneBridge's therapies.